Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04832425 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder
A Phase 2 study, sponsored by Praxis Precision Medicines.
- Completed
- Registry status
- Phase 2
- Development phase
- 216
- Enrollment target
NCT04832425: Completed Phase 2 study, sponsored by Praxis Precision Medicines.
NCT04832425 is a Phase 2 study that has completed, run by Praxis Precision Medicines. The registered enrollment target is 216 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04832425, a Phase 2 study, has completed, sponsored by Praxis Precision Medicines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 216 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo in a 1:1 ratio.
Primary Outcome
The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement.
Interventions
- DRUG Placebo
- DRUG PRAX-114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2021-03-30 |
| Est. Completion | 2022-05-05 |
| Phase | Phase 2 |
What the finished NCT04832425 record still lists
NCT04832425 is an interventional study that assigns participants to a tested intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04832425 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04832425 about?
NCT04832425 is a clinical study titled "A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder". This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo in a 1:1 ratio.
What is the current status of trial NCT04832425?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 216 participants. The study started on 2021-03-30. Estimated completion is 2022-05-05.
What interventions are being tested in trial NCT04832425?
The interventions under investigation include: Placebo (DRUG), PRAX-114 (DRUG).
Who is sponsoring clinical trial NCT04832425?
This trial is sponsored by Praxis Precision Medicines, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04832425's enrollment target sits among peer trials
216 286th of 2000 higher than 1,712 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02609685 · 216 participants · NA
Active Surveillance of Papillary Thyroid Microcarcinoma
- NCT04994873 · 216 participants · NA
Skills to Enhance Positivity in Suicidal Youth
- NCT05264779 · 216 participants · NA
The Periviable GOALS Decision Support Tool
- NCT05434130 · 216 participants · Phase 2
Modulating Exercise Dosage to Improve Concussion Recovery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI